In-tandem insight from basic science combined with clinical research: CD38 as both marker and key component of the pathogenetic network underlying chronic lymphocytic leukemia

Blood
Silvia DeaglioFabio Malavasi

Abstract

The absence of mutations in the IgV genes, together with the presence of ZAP-70 and CD38, are the most reliable negative prognostic markers for chronic lymphocytic leukemia (CLL) patients. Several lines of evidence indicate that CD38 may be not only a diagnostic marker but also a key element in the pathogenetic network in CLL. First, CD38 is a receptor that induces proliferation and increases survival of CLL cells. Second, CD38 signals start upon interaction with the CD31 ligand expressed by stromal and nurse-like cells. Third, CD38/CD31 contacts up-regulate CD100, a semaphorin involved in sustaining CLL growth. Fourth, evidence that nurselike cells express high levels of CD31 and plexin-B1, the high-affinity ligand for CD100, offers indirect confirmation for this model of receptor cross-talk. Elements of variation in the clinical course of CD38(+) CLL patients include (1) potential intersection with ZAP-70, a kinase involved in the CD38 signaling pathway in T and natural killer (NK) cells, and (2) the effects of genetic polymorphisms of the receptors involved, at least of CD38 and CD31. Consequently, CD38 together with ZAP-70 appear to be the key elements of a coreceptor pathway that may sustain the signals mediated by the B-c...Continue Reading

References

Oct 1, 1980·The Journal of Experimental Medicine·A K BhanS F Schlossman
Oct 19, 1995·The New England Journal of Medicine·C Rozman, E Montserrat
Mar 1, 1995·The Journal of Experimental Medicine·M KumagaiD Campana
Jul 1, 1994·The Journal of Experimental Medicine·V PascualJ D Capra
Mar 1, 1994·Immunology Today·F MalavasiK Mehta
Feb 1, 1996·The New England Journal of Medicine·E BeharF C Grumet
Oct 1, 1996·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·K MehtaF Malavasi
Jan 1, 1997·Tissue Antigens·A FunaroF Malavasi
May 12, 1998·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·M MorraF Malavasi
Oct 28, 1998·The Journal of Clinical Investigation·F FaisN Chiorazzi
Aug 24, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·F Caligaris-Cappio, T J Hamblin
Mar 8, 2000·Proceedings of the National Academy of Sciences of the United States of America·M T ZilberC Gelin
Apr 27, 2000·The Journal of Biological Chemistry·C MunshiH C Lee
May 23, 2000·The Journal of Immunology : Official Journal of the American Association of Immunologists·M DonoM Ferrarini
Jan 4, 2001·Leukemia Research·S DeaglioF Malavasi
Mar 22, 2001·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·S DeaglioF Malavasi
Mar 27, 2001·Annual Review of Pharmacology and Toxicology·H C Lee
Apr 3, 2001·International Immunology·R MalloneF Malavasi
Aug 8, 2001·The Journal of Immunology : Official Journal of the American Association of Immunologists·N C OttosonY Shimizu
Dec 12, 2001·Trends in Immunology·A Kumanogoh, H Kikutani
Feb 14, 2002·British Journal of Haematology·Patrice ChevallierRichard Garand
May 30, 2002·Nature Reviews. Immunology·Flavius Martin, John F Kearney

❮ Previous
Next ❯

Citations

Feb 1, 2007·Current Hematologic Malignancy Reports·Neil E Kay, Tait D Shanafelt
Feb 5, 2009·Journal of the American Chemical Society·Hong JiangHening Lin
Jun 3, 2009·Nature Reviews. Clinical Oncology·Lisa PleyerRichard Greil
Oct 20, 2010·Nature Reviews. Clinical Oncology·Paula Cramer, Michael Hallek
Nov 17, 2006·Leukemia·P DregerUNKNOWN Chronic Leukemia Working Party of the EBMT
Mar 25, 2011·Organic & Biomolecular Chemistry·Min DongHon Cheung Lee
May 16, 2007·The Journal of Experimental Medicine·Silvia DeaglioSimon C Robson
Oct 22, 2008·American Journal of Respiratory Cell and Molecular Biology·Fabienne GallyAnne-Laure Perraud
Jul 19, 2011·Blood·Fabio MalavasiNicholas Chiorazzi
Mar 24, 2007·Molecular Medicine·Fortunato MorabitoNicholas Chiorazzi
May 7, 2014·Immunology and Cell Biology·Hussein GhamlouchBrigitte Gubler
Apr 2, 2013·Leukemia & Lymphoma·Philip A Thompson, Constantine S Tam
Dec 3, 2013·Leukemia & Lymphoma·Pauline Y HuangRichard I Christopherson
Oct 26, 2011·Leukemia & Lymphoma·Pauline Y HuangRichard I Christopherson
Feb 13, 2010·Expert Opinion on Therapeutic Targets·Monica Lopez-Guerra, Dolors Colomer
Mar 23, 2011·Expert Review of Anticancer Therapy·Marco FangazioGianluca Gaidano
Feb 22, 2014·Expert Opinion on Investigational Drugs·Jacob P LaubachKenneth C Anderson
Sep 8, 2010·Seminars in Cancer Biology·Silvia DeaglioFabio Malavasi
Mar 7, 2009·Cancer Genetics and Cytogenetics·Fabiola Quintero-RiveraP Nagesh Rao
Jul 5, 2008·Blood Reviews·Femke Van BockstaeleJan Philippé
Apr 12, 2008·Trends in Molecular Medicine·Silvia DeaglioFabio Malavasi
Oct 13, 2007·Experimental and Molecular Pathology·Julius M CruseJeanann L Suggs
Aug 21, 2007·Best Practice & Research. Clinical Haematology·Terry J Hamblin
Jul 8, 2009·Annals of the New York Academy of Sciences·Richard P EbsteinNurit Yirmiya
Feb 12, 2009·Hematological Oncology·Davide Rossi, Gianluca Gaidano

❮ Previous
Next ❯

Related Concepts

Related Feeds

B-Cell Leukemia (Keystone)

B-cell leukemia includes various types of lymphoid leukemia that affect B cells. Here is the latest research on B-cell leukemia.

Cancer Biology: Molecular Imaging

Molecular imaging enables noninvasive imaging of key molecules that are crucial to tumor biology. Discover the latest research in molecular imaging in cancer biology in this feed.